Valuation: DiaSorin S.p.A.

Capitalization 3.35B 3.96B 3.09B 2.92B 5.44B 370B 5.52B 36.28B 14.2B 177B 14.85B 14.54B 629B P/E ratio 2026 *
18.7x
P/E ratio 2027 * 16.3x
Enterprise value 4.01B 4.73B 3.7B 3.49B 6.5B 442B 6.6B 43.36B 16.97B 212B 17.75B 17.38B 752B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 2.96x
Free-Float
37.75%
Yield 2026 *
2.06%
Yield 2027 * 2.28%
1 day+0.38%
1 week+6.60%
Current month+5.54%
1 month-1.09%
3 months-16.20%
6 months-14.69%
Current year-7.75%
1 week 57.24
Extreme 57.24
63.92
1 month 52.34
Extreme 52.34
65.56
Current year 52.34
Extreme 52.34
77.64
1 year 52.34
Extreme 52.34
101.6
3 years 52.34
Extreme 52.34
112.35
5 years 52.34
Extreme 52.34
208.8
10 years 49.85
Extreme 49.85
211.8
Manager TitleAgeSince
Chief Executive Officer 60 25/03/2007
Corporate Officer/Principal 63 28/04/2022
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 60 27/04/2016
Director/Board Member 63 25/03/2007
Chairman 57 28/04/2022
Change 5d. change 1-year change 3-years change Capi.($)
+0.38%+6.60%-34.12%-34.96% 3.94B
+0.49%+0.77%-19.76%-4.97% 12.77B
-1.78%-9.05%+87.91%+246.37% 11.33B
+3.76%+11.73% - - 5.71B
+1.45%+7.51%-17.81%-5.33% 5.38B
-2.85%-8.79%+105.55%+65.67% 4.79B
-1.35%-1.54%-12.87%-22.63% 5.37B
+2.22%+16.18%+206.34%-53.08% 3.17B
+0.73%-0.52%-17.93%-43.42% 2.86B
+0.77%+0.88%+31.78%+44.11% 1.9B
Average +0.38%+1.19%+36.57%+21.31% 5.72B
Weighted average by Cap. +0.11%-0.14%+31.31%+49.43%

Financials

2026 *2027 *
Net sales 1.23B 1.46B 1.14B 1.07B 2B 136B 2.03B 13.35B 5.23B 65.33B 5.47B 5.35B 232B 1.32B 1.56B 1.22B 1.15B 2.14B 145B 2.17B 14.26B 5.58B 69.76B 5.84B 5.72B 247B
Net income 181M 213M 167M 157M 293M 19.91B 297M 1.95B 765M 9.56B 800M 783M 33.88B 212M 250M 195M 184M 343M 23.3B 348M 2.29B 895M 11.19B 936M 917M 39.66B
Net Debt 655M 773M 604M 570M 1.06B 72.12B 1.08B 7.08B 2.77B 34.64B 2.9B 2.84B 123B 554M 653M 511M 482M 897M 60.99B 911M 5.99B 2.34B 29.29B 2.45B 2.4B 104B
Logo DiaSorin S.p.A.
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc. At the end of 2024, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.
Employees
3,242
Date Price Change Volume
15/04/26 63.30 +0.38% 217,407
14/04/26 63.06 +2.94% 388,020
13/04/26 61.26 +0.26% 251,451
10/04/26 61.10 +0.76% 210,217
09/04/26 60.64 0.00% 406,623
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
63.30EUR
Average target price
69.78EUR
Spread / Average Target
+10.23%

Quarterly revenue - Rate of surprise